Showing 2351-2360 of 2839 results for "".
- Exosome Diagnostics and Therapeutics Market Expected to Surgehttps://modernaesthetics.com/news/exosome-diagnostics-and-therapeutics-market-expected-to-surge/2473588/Emerging potential of exosome-based liquid biopsy is a primary factor driving the growth of the market. The Exosome Diagnostics and Therapeutics market is expected to surge from $59 million in 2024 to $6.848 billion by 2032 with a compound annual growth rate of 108.9%. The exosome
- Top Plastic Surgeon Leads Study on Stackable Medical Grade Skincarehttps://modernaesthetics.com/news/top-plastic-surgeon-leads-study-stackable-medical-grade-skincare/2473587/A new study in the Aesthetic Surgery Journal led by Few, MD, shows positive results for using a stackable skincare routine. The use of stackable skincare can help streamline patients to treat primary concerns without causing irritation that can sometimes come from patients layerin
- Men’s skincare market expected to grow by more than $6Bhttps://modernaesthetics.com/news/mens-skincare-market-expected-grow-more-than-6-billion/2473585/Skincare products targeted for men are generating massive attention and new market research estimates the market will grow by more than $6 billion over the next four years. Technavio reports a CAGR of about 7.19% from 2024 to 2028. Industry leaders are catering to t
- Alma Introduces Alma IQ With World's Most Versatile Aesthetic Workstationhttps://modernaesthetics.com/news/alma-advances-personalization-worlds-most-versatile-aesthetic-workstation-intelligence-skin-analysis-system/2473584/Alma IQ is a custom skin analysis system built to redefine and elevate the patient experience. It’s the latest innovation debuted from Alma, a global leader in energy-based medical and aesthetics solutions. The system has smart technology with 10 light mode, scanning multiple skin
- Sustainable Skincare Dispenser Introducedhttps://modernaesthetics.com/news/sustainable-skincare-dispenser-introduced/2473582/LyondellBasell has collaborated with Coradin and Dermalogica to create a dispenser for skincare and other products that is composed of more than 75% recycled material, according to a press release. The Greenis® Dispenser leverages LyondellBasell’s CirculenRecover polypropylene
- Ultrasound Solution Approved for Upper Armshttps://modernaesthetics.com/news/ultrasound-solution-approved-for-upper-arms/2473579/The upper arms are notoriously difficult to slim down, especially for those who are genetically predisposed to gain weight there. This can be further complicated for women, who, because of hormonal differences, are more likely to store fat in their upper arms. And the rise of rapid weight loss as
- Dr. Jeanine Downie Discusses Fake Botox in TV Segmenthttps://modernaesthetics.com/news/dr-jeanine-downie-discusses-fake-botox-in-tv-segment/2473578/If public awareness is the key to combatting the counterfeit Botox problem that has been popping up around the country recently, then Modern Aesthetics Editorial Board member Jeanine B. Downie, MD, FAAD, took a big step May 13. Dr. Downie joined anchor Vanessa Freeman on P
- New Four-in-One Daily Anti-Aging Moisturizerhttps://modernaesthetics.com/news/new-four-in-one-daily-anti-aging-moisturizer/2473571/Revision Skincare announced the launch of a four-in-one daily anti-aging moisturizer with broad-spectrum SPF 50 that corrects, brightens, and hydrates the skin. Intellishade® TruPhysical Clear features a sheer, oil-free, 100% mineral formula that enhances the natural radiance of all
- Aesthetic Society Names New Presidenthttps://modernaesthetics.com/news/aesthetic-society-names-new-president/2473569/The Aesthetic Society announced the appointment of Kiya Movassaghi, MD, DMD, FACS, a board-certified plastic surgeon from Eugene, Oregon, as its president, saying his leadership will focus on strategically fortifying The Society's position as the global leader in education and innov
- Elevai Labs Eyes Obesity Treatment Market with Myostatin Inhibitorshttps://modernaesthetics.com/news/elevai-labs-expands-pipeline-eyes-obesity-treatment-market-with-myostatin-inhibitors/2473568/Elevai Labs, Inc. announced that it has acquired exclusive rights to two assets (EL-22 and EL-32) aimed at preventing muscle loss and treating obesity, according to a company press release. The new assets, according to the company, involve engineered probiotics expressing myostatin and